Primus In News
Precision oncology gains ground as India clears targeted cancer therapies
25-12-2025
Nilaya Varma, Group CEO and Co-Founder,Primus Partners, highlights that the approvals represent a major step toward integrating outcome-based precision medicine into routine cancer care, with combination immunotherapies improving treatment outcomes for patient groups that previously had limited options.
Explore Related Insights
- Railway shares extend rise on Budget optimism; IRCON, Railtel, RITES, Jupiter Wagons rise up to 10%: What lies ahead?
- Rethinking the future of education in the post Covid-19 era
- Government mandates RBI approval for cross-border mergers from Sep 17
- Two-wheeler EV sales skid for first time in FY26 in July, legacy cos retain lead
